ROIV
Roivant Sciences Ltd
NASDAQ · Biotechnology
$25.82
+4.68 (+22.14%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 27.89M | 34.56M | 2.78B | 2.76B | 2.29B |
| Net Income | -164,901,066 | -183,904,534 | -113,134,495 | -140,854,131 | -104,632,272 |
| EPS | — | — | — | — | — |
| Profit Margin | -592.0% | -562.4% | -4.1% | -5.1% | -4.6% |
| Rev Growth | -19.3% | -19.3% | +17.6% | -1.7% | -7.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 8.00B | 7.19B | 7.29B |
| Total Equity | — | — | 13.59B | 12.91B | 14.47B |
| D/E Ratio | — | — | 0.59 | 0.56 | 0.50 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -940,652,435 | -1,107,335,580 | -200,438,119 | -182,068,335 | -161,653,425 |
| Free Cash Flow | — | — | -160,956,229 | -125,369,781 | -83,019,830 |